

Japan Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Test (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Product, By Test Type, By End Use, And Segment Forecasts, 2025 - 2033

<https://marketpublishers.com/r/J3764457F2CAEN.html>

Date: September 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: J3764457F2CAEN

Abstracts

Market Size & Trends

The Japan autoimmune disease diagnostics market size was estimated at USD 365.49 million in 2024 and is expected to reach USD 640.45 million by 2033, growing at a CAGR of 6.6% from 2025 to 2033. As the world's fastest-aging nation, with over 29% of its population aged 65 or older, Japan faces a rising prevalence of conditions such as rheumatoid arthritis and autoimmune pancreatitis. This fuels demand for ANA tests, autoantibody panels, and advanced molecular assays. Growth is further supported by innovations in multiplex immunoassays, AI, and biomarker discovery, alongside strong academic-industry collaborations. Partnerships, such as those involving Sysmex, MBL, and Autobio Diagnostics, enhance precision, scalability, and early disease detection.

According to the Statistics Bureau of Japan (October 2023), the country's population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year—marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.

This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.

Japan Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Japan autoimmune disease diagnostics market based on type, product, test type, and end use:

Type Outlook (Revenue, USD Million, 2021 - 2033)

Systemic autoimmune disease diagnostics

- Rheumatoid arthritis

- Ankylosing spondylitis diagnostics

- Systemic lupus erythematosus (SLE)

- Others

Localized autoimmune disease diagnostics

- Multiple sclerosis

- Type 1 diabetes

- Hashimoto's Thyroiditis

- Idiopathic thrombocytopenic purpura

- Others

Product Outlook (Revenue, USD Million, 2021 - 2033)

Instruments

Consumables & Assays

Test Type Outlook (Revenue, USD Million, 2021 - 2033)

Antinuclear antibody tests

Indirect Immunofluorescence (IIF) ANA tests

ELISA-based ANA tests

Multiplex/line immunoassay ANA panels

Others

Autoantibody tests

Rheumatoid Factor (RF) tests

Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests

Anti-dsDNA tests

Anti-Smith (Sm) antibody tests

Anti-Ro/SSA & Anti-La/SSB antibody tests

Others

C-reactive Protein (CRP)

Complete blood count (CBC)

Urinalysis

Others

End Use Outlook (Revenue, USD Million, 2021 - 2033)

Hospitals

Diagnostic Centers

Others

This report can be delivered to the clients within 2 Business Days

Contents

CHAPTER 1. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
 - 1.1.1. Segment Definitions
 - 1.1.1.1. Type Segment
 - 1.1.1.2. Technology Segment
 - 1.1.1.3. End Use Segment
- 1.2. Estimates and Forecast Timeline
- 1.3. Objectives
 - 1.3.1. Objective -
 - 1.3.2. Objective -
 - 1.3.3. Objective -
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information or Data Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations

CHAPTER 2. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Type and Product Snapshot
- 2.3. Test Type and End Use Snapshot
- 2.4. Competitive Landscape Snapshot

CHAPTER 3. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
 - 3.2.1. Parent Market Outlook
 - 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
 - 3.4.1. Rising demand for early and non-invasive diagnosis
 - 3.4.2. Technological advancements
 - 3.4.3. Academic-industry collaborations
- 3.5. Market Restraint Analysis
 - 3.5.1. High cost and limited reimbursement coverage
- 3.6. Market Opportunity Analysis
 - 3.6.1. Expansion of personalized medicine and biomarker-based testing
- 3.7. Porter's Five Forces Analysis
- 3.8. PESTLE Analysis

CHAPTER 4. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS

- 4.1. Japan Autoimmune Disease Diagnostics Market: Type Movement Analysis
- 4.2. Systemic autoimmune disease diagnostics
 - 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.2.2. Rheumatoid arthritis
 - 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.2.3. Ankylosing spondylitis diagnostics
 - 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.2.4. Systemic lupus erythematosus (SLE)
 - 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.2.5. Others
 - 4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3. Localized autoimmune disease diagnostics
 - 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.3.2. Multiple sclerosis
 - 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.3.3. Type 1 diabetes
 - 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 4.3.4. Hashimoto's Thyroiditis
 - 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

- 4.3.5. Idiopathic thrombocytopenic purpura
 - 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.6. Others
 - 4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 5. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 5.1. Japan Autoimmune Disease Diagnostics Market: Product Movement Analysis
- 5.2. Instruments
 - 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. Consumables & Assays
 - 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Mass spectrometry-based assays

CHAPTER 6. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS

- 6.1. Japan Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
- 6.2. Antinuclear antibody tests
 - 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.2.2. Indirect Immunofluorescence (IIF) ANA tests
 - 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.2.3. ELISA-based ANA tests
 - 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.2.4. Multiplex/line immunoassay ANA panels
 - 6.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.2.5. Others
 - 6.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Autoantibody tests
 - 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.3.2. Rheumatoid Factor (RF) tests
 - 6.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.3.3. Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
 - 6.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.3.4. Anti-dsDNA tests
 - 6.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
 - 6.3.5. Anti-Smith (Sm) antibody tests
 - 6.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.3.6. Anti-Ro/SSA & Anti-La/SSB antibody tests

6.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.3.7. Others

6.3.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.4. C-reactive Protein (CRP)

6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.5. Complete blood count (CBC)

6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.6. Urinalysis

6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.7. Others

6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 7. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS

7.1. Japan Autoimmune Disease Diagnostics Market: End Use Movement Analysis

7.2. Hospitals

7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

7.3. Diagnostic Centers

7.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

7.4. Others

7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Company Categorization

8.2. Strategy Mapping

8.2.1. NEW PRODUCT LAUNCH

8.2.2. PARTNERSHIPS

8.2.3. ACQUISITION

8.2.4. COLLABORATION

8.2.5. FUNDING

8.3. Key Company Market Share Analysis, 2024

8.4. Company Heat Map Analysis

8.5. Company Profiles

8.5.1. Fujirebio

8.5.2. SEKISUI MEDICAL CO., LTD

8.5.2.1. Company Overview

- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Medical & Biological Laboratories (MBL)
 - 8.5.3.1. Company Overview
 - 8.5.3.2. Financial Performance
 - 8.5.3.3. Product Benchmarking
 - 8.5.3.4. Strategic Initiatives
- 8.5.4. Bio-Rad Laboratories, Inc.
 - 8.5.4.1. Company Overview
 - 8.5.4.2. Financial Performance
 - 8.5.4.3. Product Benchmarking
 - 8.5.4.4. Strategic Initiatives
- 8.5.5. Abbott
 - 8.5.5.1. Company Overview
 - 8.5.5.2. Financial Performance
 - 8.5.5.3. Product Benchmarking
 - 8.5.5.4. Strategic Initiatives
- 8.5.6. F. Hoffmann-La Roche, Ltd.
 - 8.5.6.1. Overview
 - 8.5.6.2. Financial Performance
 - 8.5.6.3. Product Benchmarking
 - 8.5.6.4. Strategic Initiatives
- 8.5.7. Siemens Healthineers AG
 - 8.5.7.1. Company Overview
 - 8.5.7.2. Financial Performance
 - 8.5.7.3. Product Benchmarking
 - 8.5.7.4. Strategic Initiatives
- 8.5.8. Sysmex Corporation
 - 8.5.8.1. Grifols Company Overview
 - 8.5.8.2. Financial Performance
 - 8.5.8.3. Product Benchmarking
 - 8.5.8.4. Strategic Initiatives
- 8.5.9. BioMérieux
 - 8.5.9.1. Company Overview
 - 8.5.9.2. Financial Performance
 - 8.5.9.3. Product Benchmarking
 - 8.5.9.4. Strategic Initiatives
- 8.5.10. Beckman Coulter (Danaher)

- 8.5.10.1. Company Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1 List Of Abbreviation

Table 2 Japan Autoimmune Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)

Table 3 Japan Autoimmune Disease Diagnostics Market, By Product, 2021 - 2033 (USD Million)

Table 4 Japan Autoimmune Disease Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)

Table 5 Japan Autoimmune Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Market summary
- Fig. 4 Market segmentation & scope
- Fig. 5 Market size and growth prospects
- Fig. 6 Japan autoimmune disease diagnostics market - Key market driver analysis
- Fig. 7 Japan autoimmune disease diagnostics market - Key market restraint analysis
- Fig. 8 Penetration & growth prospect mapping
- Fig. 9 Japan autoimmune disease diagnostics market - Porter's analysis
- Fig. 10 Japan autoimmune disease diagnostics market - PESTEL analysis
- Fig. 11 Japan autoimmune disease diagnostics market Type outlook key takeaways
- Fig. 12 Japan autoimmune disease diagnostics market : Type movement analysis
- Fig. 13 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 14 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
- Fig. 15 Ankylosing spondylitis diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 16 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 17 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
- Fig. 18 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
- Fig. 19 Hashimoto's Thyroiditis market estimates, 2021 - 2033 (USD Million)
- Fig. 20 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
- Fig. 21 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 22 Japan autoimmune disease diagnostics market product outlook key takeaways
- Fig. 23 Japan autoimmune disease diagnostics market : product movement analysis
- Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
- Fig. 25 Consumables & Assays market estimates, 2021 - 2033 (USD Million)
- Fig. 26 Japan autoimmune disease diagnostics market Test type outlook key takeaways
- Fig. 27 Japan autoimmune disease diagnostics market : Test type movement analysis
- Fig. 28 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
- Fig. 29 Indirect Immunofluorescence (IIF) ANA tests market estimates, 2021 - 2033 (USD Million)
- Fig. 30 ELISA-based ANA tests market estimates, 2021 - 2033 (USD Million)
- Fig. 31 Multiplex/line immunoassay ANA panels market estimates, 2021 - 2033 (USD Million)

Million)

Fig. 32 Others market estimates, 2021 - 2033 (USD Million)

Fig. 33 Autoantibody tests market estimates, 2021 - 2033 (USD Million)

Fig. 34 Rheumatoid Factor (RF) tests estimates, 2021 - 2033 (USD Million)

Fig. 35 Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests estimates, 2021 - 2033 (USD Million)

Fig. 36 Anti-dsDNA tests estimates, 2021 - 2033 (USD Million)

Fig. 37 Anti-Smith (Sm) antibody tests estimates, 2021 - 2033 (USD Million)

Fig. 38 Anti-Ro/SSA & Anti-La/SSB antibody tests estimates, 2021 - 2033 (USD Million)

Fig. 39 Others estimates, 2021 - 2033 (USD Million)

Fig. 40 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)

Fig. 41 Complete blood count (CBC) market estimates, 2021 - 2033 (USD Million)

Fig. 42 Urinalysis market estimates, 2021 - 2033 (USD Million)

Fig. 43 Others market estimates, 2021 - 2033 (USD Million)

Fig. 44 Japan autoimmune disease diagnostics market end use outlook key takeaways

Fig. 45 Japan autoimmune disease diagnostics market : end use movement analysis

Fig. 46 Hospitals market estimates, 2021 - 2033 (USD Million)

Fig. 47 Diagnostic Centers market estimates, 2021 - 2033 (USD Million)

Fig. 48 Others market estimates, 2021 - 2033 (USD Million)

Fig. 49 Strategy framework

I would like to order

Product name: Japan Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Test (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Product, By Test Type, By End Use, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/J3764457F2CAEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/J3764457F2CAEN.html>